Loading MIRM detail
Loading ticker data...
Loading MIRM detail
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases.
The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis.
Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.
Chart data unavailable
STOCKHOLM, SE / ACCESS Newswire / April 9, 2026 / Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (STO:EGTX), today announced the appointment of Tiago Nunes, MD, PhD, as Chief Medical Officer (CMO), effective May 1, 2026. Tiago Nunes is an experienced clinical development leader, with significant expertise advancing rare disease therapeutics through regulatory approval and launch, having most recently served as Senior Vice President, Clinical Development at Mirum Pharmaceuticals (NASDAQ: MIRM).
SG Americas Securities LLC acquired a new stake in Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 18,710 shares of the company's stock, valued at approximately $1,478,000. A number of other hedge funds and other institutional investors
Shares of Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM - Get Free Report) have earned an average rating of "Moderate Buy" from the fourteen analysts that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, twelve have assigned a buy rating and one has assigned a strong buy rating
Mirum Pharmaceuticals (MIRM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. What's next for the stock?
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM - Get Free Report) CEO Christopher Peetz sold 40,985 shares of the business's stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $91.98, for a total transaction of $3,769,800.30. Following the transaction, the chief executive officer owned 194,309 shares in the company, valued
MIRM completes enrollment in phase III EXPAND study of Livmarli for treating additional rare cholestatic liver diseases. Top-line data due in Q4 2026.
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Completes Enrollment in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Additional Rare Cholestatic Liver Diseases.
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Shares of Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM - Get Free Report) have earned an average rating of "Moderate Buy" from the fourteen analysts that are covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, twelve have issued a buy rating and one has assigned a strong buy rating
MIRM completes enrollment in phase III AZURE-1 and screening in AZURE-4 for brelovitug in HDV, with top-line data expected in the second half of 2026.
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Provides AZURE Clinical Program Update for brelovitug in Chronic Hepatitis Delta Virus.
MIRM posts Q4 loss. Revenues jump 50% on strong Livmarli and bile acid drug sales, topping estimates in Q4 2025 and lifting shares.
Although the revenue and EPS for Mirum Pharmaceuticals (MIRM) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Mirum Pharmaceuticals, Inc. (MIRM) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of $0.02. This compares to a loss of $0.49 per share a year ago.
